Details for Patent: 10,654,827
✉ Email this page to a colleague
Which drugs does patent 10,654,827 protect, and when does it expire?
Patent 10,654,827 protects SUNLENCA and is included in two NDAs.
This patent has ninety-five patent family members in forty-four countries.
Summary for Patent: 10,654,827
| Title: | Therapeutic compounds |
| Abstract: | The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus. |
| Inventor(s): | Michael Graupe, Steven J. Henry, John O. Link, Roland D. SAITO, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US16/016,718 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,654,827
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Start Trial | ||||
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,654,827
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3347352 | ⤷ Start Trial | CA 2022 00052 | Denmark | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | 301212 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | PA2023501 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | 122022000082 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
